Why You Should Watch Sarepta Therapeutics Today

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

Good morning, fellow Fools! It's time to check in on the health-care stocks making headlines this morning.

Sarpeta gets a notable backer
Sarepta Therapeutics (NASDAQ: SRPT  ) is up on heavy volume this morning after receiving a favorable mention from notable biotech investor Joseph Edelman over the weekend. Specifically, Edelman said that he believes Sarepta's Duchenne muscular dystrophy, or DMD, drug eteplirsen will eventually get approved by the Food and Drug Administration, and the drug could see eye-popping sales of $4 billion in the U.S. alone. He also suggested that Sarepta looks to have the highest remaining upside of any mid-cap biotechs right now.

As a refresher, the FDA rejected Sarepta's request for an accelerated approval for eteplirsen last November because the mid-stage trial only enrolled 12 patients. Essentially, the FDA is concerned that there is currently insufficient data to properly assess the drug's effectiveness and safety profile. As a result, the agency wants Sarepta to perform a much larger late-stage trial prior to submitting a New Drug Application, or NDA, for eteplirsen. After discussing the issue with the FDA, Sarepta now plans on initiating the new trial next year.

Upon receiving the bad news, Sarepta shares plummeted more than 75% in a single day. However, Sarepta has now rallied more than 30% since this time and continues to head upwards this morning.

Why was Sarepta's drug denied?
Many experts in the sector view eteplirsen's rejection to be the result of GlaxoSmithKline (NYSE: GSK  ) and Prosensa's (UNKNOWN: RNA.DL  ) DMD drug drisapersen failing to provide any clinically meaningful benefit to patients in a late-stage trial. Namely, drisapersen looked like a promising DMD treatment at the mid-stage level as well, but the late-stage results dashed any hopes that a breakthrough DMD therapy was close at hand. And because the two therapies are broadly similar in that they skip mutated genetic sequences that lead to the production of dysfunctional muscular proteins, the FDA appears to be concerned that eteplirsen may also fail in a larger late-stage study.

Foolish outlook
Personally, I am skeptical about eteplirsen's chances for success in a late-stage trial. While it is a more potent drug that drisapersen and can be dosed at higher levels, it remains to be seen if the drug does in fact work. While eteplirsen's dramatic effects on some patients afflicted with DMD are reasons to be optimistic, you should understand that these are preliminary results, and this is how the FDA views the matter as well. Moreover, drisapersen looked extremely promising early on and that turned out to be a false indicator of the drug's ultimate fate. In sum, my take is that Sarepta currently doesn't offer much of a discount with a market cap over $700 million compared to the clinical and regulatory risks surrounding the company's lead drug candidate. As such, Foolish investors might want to wait until the drug's regulatory fate is better understood than it is today.

A top stock to check out instead
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (3) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 30, 2013, at 9:29 AM, tredleon wrote:

    Your comments are way off base. The FDA did not reject SRPT's "request for accelerated approval" because their trial only enrolled 12 patients. The FDA knew since day one the trial only enrolled 12 patients and advised them earlier in the year to submit an application for approval based on the results to-date. The FDA changed their stance in November because they had a knee-jerk reaction to the Drisa failure (they did not have any detailed data from that study in Nov when they advised SRPT to hold off) and their careless analysis of natural history data - indicating that the natural history data shows stability in SRPT's patient population, where in fact the opposite is true. It is clear from your "skepticism" that you haven't been following SRPT for very long and you have a rudimentary understanding about the issues the company and FDA are dealing with.

  • Report this Comment On December 30, 2013, at 12:07 PM, Biotecher wrote:

    Your comments are right on target.

    There is no objective evidence today that eteplirsen has any effect. It only works when you eliminate non responders from the analysis, the so-called Modified Intent To Treat analysis.

    What yo failed to mention however is that Joseph Edelman's Perceptive Advisor fund owned over 2.7 Million shares of Sarepta as of the end of September (the fund second largest holding) for a $130 Million value at that time. It is very likely the position was the same in mid November when SRPT stock value went down 75%.

    So Perceptive has taken a hug bath with this stock and Mr Edelman is just pumping up the stock so as to recover some of his losses.

  • Report this Comment On December 30, 2013, at 1:05 PM, lobfool wrote:

    "There is no objective evidence today that eteplirsen has any effect..."


    Who are the "non-responders"? The 12 boys in the study have all stabilized or IMPROVED. The two oldest boys in the Eteplirsen study (twins) lost ambulation before the drug took effect, however they have stabilized.

    The parents of the kids in the study are AMAZED as what they are seeing is MIRACULOUS. Eteplirsen works, the kids know it, the parents know it and the doctors participating in the ongoing study know it.

    Eteplirsen is a game-changer, while the GSK - Prosensa drug drispersen is a toxic kidney killer.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2778691, ~/Articles/ArticleHandler.aspx, 9/26/2016 7:00:35 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,094.83 -166.62 -0.91%
S&P 500 2,146.10 -18.59 -0.86%
NASD 5,257.49 -48.26 -0.91%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/26/2016 4:02 PM
GSK $42.96 Down -0.46 -1.06%
GlaxoSmithKline CAPS Rating: ***
RNA.DL $0.00 Down +0.00 +0.00%
Prosensa Holding CAPS Rating: **
SRPT $59.66 Up +1.83 +3.16%
Sarepta Therapeuti… CAPS Rating: **